Secondary analysis of three phase 3 switch trials (1227 virologically suppressed adults with HIV-1): HIV-1 RNA <50 copies/mL at week 48 on doravirine/islatravir was ≥88% with or without baseline proviral NNRTI RAMs (26.3%) or M184I/V (5.7%).
Secondary analysisn = 1,227
Diamond et al. Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA